4.3 Article

Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007

期刊

DIABETIC MEDICINE
卷 27, 期 8, 页码 938-948

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1464-5491.2010.03040.x

关键词

cost effectiveness; diabetes; prescribing; resource use; trend

资金

  1. Astellas
  2. Diabetes UK
  3. European Association
  4. Engineering and Physical Sciences Research Council
  5. Ferring
  6. GSK
  7. Lilly
  8. Medtronic
  9. Medical Research Council
  10. Pfizer
  11. Sanofi-Aventis
  12. National Health Service
  13. Wyeth

向作者/读者索取更多资源

P>Aims The purpose of this study was to characterize the financial cost and efficacy of primary care treatment for diabetes in the United Kingdom from 1997 to 2007. Methods Retrospective data were analysed for people with Type 1 and Type 2 diabetes along with matched control subjects using data from The Health Improvement Network. Costs were attributed from published sources and adjusted for price inflation. Type 2 diabetes was analysed by five commonly used treatment regimens. Results It was possible to identify 126 052 people for inclusion: 11 300 (8.9%) with Type 1 diabetes and 114 752 (91.1%) with Type 2. The overall mean prescribing costs per person per year (pppy) increased markedly for people with diabetes from 1997 to 2007: for Type 1, from 573 pound to 1014 pound pppy (+77%), and for Type 2, from 39 pound to 740 pound pppy (+89%). In 2007, diabetes-treatment-specific prescribing represented 57% of prescribing costs in Type 1 diabetes and 28% in Type 2 diabetes. In Type 2 diabetes there was a mean of 5.4 primary care consultations in 1997, increasing to 11.5 pppy in 2007 (+112%). In 1997 the total mean cost of primary care treatment for Type 2 diabetes was 602 pound pppy, increasing to 1080 pound in 2007. In Type 1 diabetes, the mean glycated haemoglobin decreased by 0.1% from 8.8% in 2001 to 8.7% in 2007; the corresponding change using insulin in Type 2 diabetes was also 0.1%. Greater improvement in blood pressure and lipids was evident. Conclusions Over the 10 year period to 2007, diabetes-related primary care adjusted costs increased considerably, whereas glycated haemoglobin values did not improve at all over the same period.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据